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Abstract
Background: Superoxide dismutase-2 (SOD2) is considered one of the most important antioxidant enzymes that
regulate cellular redox state in normal and tumorigenic cells. Overexpression of this enzyme in lung, gastric,
colorectal, breast cancer and cervical cancer malignant tumors has been observed. Its relationship with inguinal
lymph node metastasis in penile cancer is unknown.
Methods: SOD2 protein expression levels were determined by immunohistochemistry in 125 usual type squamous
cell carcinomas of the penis from a Brazilian cancer center. The casuistic has been characterized by means of
descriptive statistics. An exploratory logistic regression has been proposed to evaluate the independent predictive
factors of lymph node metastasis.
Results: SOD2 expression in more than 50% of cells was observed in 44.8% of primary penile carcinomas of the usual
type. This expression pattern was associated with lymph node metastasis both in the uni and multivariate analysis.
Conclusions: Our results indicate that SOD2 expression predicts regional lymph node metastasis. The potential clinical
implication of this observation warrants further studies.
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Background
Malignant penile tumors are rare in developed countries
but exhibit relatively high prevalence in some developing
countries. Regional lymph node metastasis is one of the
most important prognostic factors in patients with
penile carcinoma due to its correlation with the ad-
vanced pathological stage of the tumor and tumor-
related death [1]. Other factors affecting prognosis are
histological grade, tumor thickness, perineural invasion,
lymphovascular invasion and pattern of invasion [2,3].
About 50% of the cases in which palpable suspicious
lymph node were present, subsequent pathologic ana-
lysis failed to find any evidence of metastatic disease in
the lymph nodes [4,5]. Conversely, 20% of lymph nodes
with no clinical signal of disease display micro meta-
stases [6]. Therefore there is a need to identify other
markers that may predict the occurrence of inguinal me-
tastasis, perineural and vascular invasion. The use of
these markers could be valuable to better define the sub-
set of patients that will benefit from different therapeutic
approaches [2-7].
Several studies have shown that superoxide dismutase
2 (SOD2 or manganese superoxide dismutase) protein
expression is up-regulated in colorectal, lung, gastric/
esophageal, and cervical cancer cells when compared to
normal tissues [8-11]. However, the relationship between
SOD2 expression and penile cancer has not been ad-
dressed, mainly in terms of regional lymph node metas-
tasis. This study aimed to evaluate the association of
SOD2 immunoexpression with inguinal lymph node me-
tastasis and its clinical implication.
Methods
Tissue samples
Penile samples from 125 patients were obtained from
the Department of Anatomic Pathology, Medical and
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Research Center, A. C. Camargo Cancer Center, São
Paulo, Brazil. No patient had distant metastasis at the
diagnosis and all of them underwent tumor resection
between 1953 and 2000. Lymphadenectomy has been
performed in 50.4% of the cases and no patient received
postoperative radiotherapy. Pathologic T stage was clas-
sified according to the TNM system of the International
Union Against Cancer, 7th edition [12]. Ethical approval
for this study was granted by the Hospital A.C. Camargo
Institutional Research Ethics Committee (Project Number
1369/10).
Lymph node status has been defined using the patho-
logic information from the lymphadenectomy performed
in 63 men (pN status). Patients who had not undergone
lymph node resection had their lymph node status based
on a retrospective longitudinal analysis of regional re-
currence. Since no patient received inguinal or pelvic ra-
diation as part of the treatment, those cases with no
lymphadenectomy and no regional recurrence in a
3-year follow-up period had their lymph node status
classified as “negative” (n = 46). Nevertheless, nine men
without lymphadenectomy developed lymphonodal
metastatic recurrence during follow-up after penectomy
(median time to recurrence: 7.1 months; range: 1.4 –
22.1 months) and consequently they were considered as
having “positive nodes” (tumor progression not previ-
ously detected). It was not possible to clearly define the
regional lymph node status in seven cases with no previ-
ous lymphadenectomy. Although they did not have re-
gional recurrence, the follow-up period was less than
three years (median follow-up: 24.1 months; range: 8.7 –
35.8 months). These samples were not included in the
uni and multivariate analyses.
Immunohistochemical SOD2 detection
After deparaffinization in xylene and rehydration, anti-
gen retrieval was performed by incubation in boiling
citrate buffer pH 6.0 for 20 minutes. Endogenous pe-
roxidase activity was inactivated with 3% hydrogen
peroxide. Nonspecific avidin-binding was also blocked
(DAKO, X0590, Carpinteria, CA, USA). Samples were
incubated with an anti-SOD2 polyclonal antibody (Santa
Cruz Biotechnology, sc-18504, Santa Cruz, CA, USA),
1:100 in 1% bovine serum albumin-phosphate buffered
solution for 30 minutes at 37°C and for 18 hours at 4°C.
Slides were then incubated for 30 minutes at 37°C with
biotinylated rabbit anti-goat IgG, (Vector, BA5000, Bur-
lingame, CA, USA) diluted 1:500, followed by incubation
for 30 minutes at 37°C with the complex streptavidin
and peroxidase (StreptABComplex/HRP Duet Mouse/
Rabbit, DakoCytomation, K0492, Glostrup, Denmark),
diluted 1:200 and developed using 100 mg of 3,3’-
diaminobenzidine tetrahydrochloride (Sigma, D-5637,
St Louis, MO, USA), 6% H2O2 in dimethyl sulphoxide
and counterstained with Harris' hematoxylin. Sections de-
rived from an ovarian papillary serous adenocarcinoma
were used as a positive control for SOD2 expression.
In order to verify the specimen quality for immuno-
histochemistry, all samples were also checked using a
cytokeratin panel, which was positive in all cases. In
addition, positivity rate of SOD2 expression was ana-
lyzed according to the year of patient’s admission (1950–
1959; 1960–1969; 1970–1979; 1980–1989; 1990–2000)
and no statistically significant difference was found.
Thus, specimen quality was considered adequate for
analysis.
Evaluation of tissue staining
Positive immunohistochemical reactions were evaluated
considering the percentage of stained tumoral cells. Only
tissue cores with more than 25% of tumor cells were an-
alyzed. The evaluation was performed by examining the
tumor core under X200 magnification. For the statistical
analysis, reactions were scored as exhibiting less than
50% stained cells or more than 50% stained cells, as pre-
viously reported by our group [11]. Immunohistochemi-
cal evaluation was performed independently and blindly
by two observers (ALF and FAS). The very few discord-
ant results were discussed by both observers and a final
score was established.
Statistical analysis
The casuistic has been characterized by means of de-
scriptive statistics. Fisher’s exact test was employed to
compare categorical variables in the univariate analysis.
Exploratory logistic regression has been proposed to
evaluate the independent predictive factors of inguinal
lymph node metastasis. Variables with p value less than
0.10 were included in the multivariate model, which was
conducted using a stepwise forward technique. The sig-
nificance level was set at 5% for all tests.
DNA extraction
For DNA extraction, several 5 μm sections of the
paraffin-embedded samples were collected in 1.5-ml
microtubes. Samples were treated with xylene and
digested with proteinase-K according to standard proto-
cols described previously [13]. The microtome blade was
changed after each block was cut and all the surround-
ing area and apparatus were cleaned with xylene and
ethanol after processing each sample to avoid contami-
nation between the samples. DNA quality was checked
by amplification of the human β-globin gene using
PCO3+/PCO4+ primers [14].
HPV typing
HPV detection and genotyping using generic primers
(GP5+/GP6+) and type specific probes (6, 11, 16, 18, 31,
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33, 35, 39, 42, 45, 51, 52, 53, 54, 55, 56 and 58), respec-
tively, was performed as previously described [15].
Results
In the present study we have analyzed by immunohisto-
chemistry the association of SOD2 expression pattern
with different tumor aggressiveness and progression vari-
ables in 125 primary SCC samples of the usual histological
type. Characterization of the population studied is de-
picted in Table 1. A representative immunostaining for
SOD2 in different penile tumor samples exhibiting <50%
or >50% stained cells is presented in Additional file 1.
Most of the cases was classified as pT2 or pT3 (87.2%)
and 44 cases had regional lymph node metastasis at diag-
nosis. No cases with distant metastasis were observed.
Fifty six tumors (44.8%) had SOD2 expression greater
than 50%. In about 20% of the cases HPV infection was
detected [see Additional file 2]. No relationship was ob-
served between presence of HPV DNA and SOD2 expres-
sion (Table 2).
Table 3 shows the regional lymph node status accor-
ding to the clinical and pathological variables. In the
bivariate analysis, metastatic node was associated with
palpable suspicious lymph node in the clinical exam
(P < 0.001), tumor size (P = 0.045), histological grade
(P = 0.013), perineural invasion (P < 0.001), vascular inva-
sion (P = 0.010), tumor depth (P = 0.002) and SOD2 ex-
pression (P = 0.002). All these variables were included in
the exploratory logistic regression (Table 4), which
identified the following independent predictive factors
of lymph node metastasis: palpable suspicious nodes
(OR = 8.9; 95% CI: 2.7 – 29.2), tumor depth greater than
5 mm (OR = 11.6; 95% CI: 1.4 – 97.1), perineural inva-
sion (OR = 9.6; 95% CI: 2.7 – 33.6) and SOD2 expression
greater than 50% (OR = 3.4; 95% CI: 1.1 – 10.1).
Table 1 Characterization of the population study (n = 125)
Variable Category N %
Age <50 yo 43 34.4
50 – 59 yo 41 32.8
≥60 yo 41 32.8
pT (TNM) pT1a 7 5.6
pT1b 4 3.2
pT2 52 41.6
pT3 57 45.6
pT4 5 4.0
Palpable suspicious regional lymph node No 64 51.2
Yes 59 47.2
Unknown 2 1.6
Regional lymph node status No metastasis 74 59.2
Metastasis 44 35.2
Unknown 7 5.6
Pattern of invasion Pushing 14 11.2
Infiltrating 101 80.8
Unknown 10 8.0
Histological grade Grade 1 15 12.0
Grade 2 45 36.0
Grade 3 65 52.0
Perineural invasion No 83 66.4
Yes 35 28.0
Unknown 7 5.6
Vascular invasion No 85 68.0
Yes 33 26.4
Unknown 7 5.6
Invasion of corpora cavernous No 22 17.6
Yes 60 48.0
Missing data 43 34.4
Invasion of corpora spongiosum No 4 3.2
Yes 88 70.4
Unknown 33 26.4
Invasion of urethra No 42 33.6
Yes 28 22.4
Unknown 55 44.0
Tumor depth ≤5 mm 21 16.8
>5 mm 92 73.6
Unknown 12 9.6
HPV detection No 99 79.2
Yes 26 20.8
SOD2 expression <50% 69 55.2
>50% 56 44.8
Table 2 Number and percentage of cases according to
HPV genotype and SOD2 expression
SOD2 < 50% SOD2 > 50%
HPV genotype (*) Category N (%) N (%) P value
HPV-16 No 59 (54.6) 49 (45.4) 0.799
Yes 10 (58.8) 7 (41.2)
HPV-18 No 64 (54.2) 54 (45.8) 0.458
Yes 5 (71.4) 2 (28.6)
HPV non-16/non-18 No 67 (55.8) 53 (44.2) 0.656
Yes 2 (40.0) 3 (60.0)
High risk HPV No 54 (53.5) 47 (46.5) 0.497
Yes 15 (62.5) 9 (37.5)
(*) HPV-16 (n = 17), HPV-18 (n = 7); HPV-11 (n = 3); HPV-6 (n = 3); HPV-35 (n = 1);
HPV-39 (n = 1). HPV co-infection has been registered in four cases: HPV-6,
11 (n = 2); HPV 6, 11 and 16 (n = 1); HPV-16, 18 and 39 (n = 1).
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Table 5 summarizes the patient’s distribution accor-
ding to the four predictive factors of inguinal lymph
node metastasis found in the multivariate model.
Discussion
To the best of our knowledge, this is the first study ana-
lyzing the expression of SOD2 in a large series of penile
carcinoma samples. SOD2 is one of three distinct super-
oxide dismutases isoforms found in mammals. This pro-
tein is found generally in the mitochondrial matrix and
is an evolutionary conserved enzyme in a variety of or-
ganisms. Superoxide dismutases act as part of the cellu-
lar antioxidant system protecting the redox sensitive
cellular machinery from damage induced by reactive
oxygen species (ROS). This enzyme’s activity affects im-
portant cellular processes including cell growth, prolifer-
ation and differentiation. As a consequence the role of
SOD2 in cancer is complex and multifactorial. In fact,
the exact role of SOD2 and redox state in cancer onset
and progression remains poorly understood. Interes-
tingly, accumulating evidence suggest that reducing oxi-
dative stress levels by increasing SOD2 expression may
represent a double-edged sword in tumor development.
Reducing oxidative stress may have anti-tumoral effect
by preventing DNA damage. This is supported by the
observation that SOD2 expression can reduce the
Table 3 Number and percentage of cases with and without regional lymph node metastasis according to clinical and
pathological variables
No lymph node metastasis Lymph node metastasis
Variable Category N (%) N (%) P value
Age < 50 yo 26 (65.0) 14 (35.0) 0.682
50 – 59 yo 27 (65.9) 14 (34.1)
≥60 yo 21 (56.8) 16 (43.2)
Palpable suspicious regional No 48 (84.2) 9 (15.8) <0.001
Lymph node Yes 24 (40.7) 35 (59.3)
pT (TNM) pT1a 7 (100.0) 0 (0.0) 0.045
> pT1a 67 (60.4) 44 (39.6)
Pattern of invasion Pushing 6 (46.2) 7 (53.8) 0.368
Infiltrating 60 (61.9) 37 (38.1)
Histological grade Grade 1 13 (86.7) 2 (13.3) 0.013
Grade 2 30 (71.4) 12 (28.6)
Grade 3 31 (50.8) 30 (49.2)
Perineural invasion No 59 (75.6) 19 (24.4) <0.001
Yes 9 (26.5) 25 (73.5)
Vascular invasion No 55 (68.8) 25 (31.2) 0.010
Yes 13 (40.6) 19 (59.4)
Invasion of corpora cavernous No 14 (66.7) 7 (33.3) 0.303
Yes 28 (50.9) 27 (49.1)
Invasion of corpora spongiosum No 3 (75.0) 1 (25.0) 1.000
Yes 50 (60.2) 33 (39.8)
Invasion of urethra No 26 (66.7) 13 (33.3) 0.436
Yes 14 (56.0) 11 (44.0)
Tumor depth ≤5 mm 18 (90.0) 2 (10.0) 0.002
>5 mm 44 (51.2) 42 (48.8)
HPV-16 No 64 (62.1) 39 (37.9) 1.000
Yes 10 (66.7) 5 (33.3)
HPV-18 No 68 (61.3) 43 (38.7) 0.255
Yes 6 (85.7) 1 (14.3)
SOD2 expression <50% 49 (75.4) 16 (24.6) 0.002
>50% 25 (47.2) 28 (52.8)
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Table 4 Predictive factors for regional lymph node metastasis according to the exploratory logistic regression
Variable Category N Adjusted OR (*) 95% CI P value
Palpable suspicious regional lymph node No 49 1.0 Reference
Yes 55 8.9 2.7 – 29.2 <0.001
Tumor depth ≤5 mm 20 1.0 Reference
>5 mm 84 11.6 1.4 – 97.1 0.023
Perineural invasion No 71 1.0 Reference
Yes 33 9.6 2.7 – 33.6 <0.001
SOD2 expression <50% 57 1.0 Reference
>50% 47 3.4 1.1 – 10.1 0.029
(*) Number of outcomes included in the analysis: 44 (regional lymph node metastasis).
OR: Odds ratio 95% CI: 95% confidence interval.
Table 5 Distribution of patients according to the combination of the predictive factors of inguinal lymph node
metastasis found in the multivariate model
Palpable suspicious
lymph node
Tumor
depth
Perineural
invasion
SOD2 expression
(>50%)
Patients
at risk Patients with inguinal lymph node metastasis
n n (%)
No (*1) ≤5 mm Absent - 9 0 (0.0)
Absent + 4 0 (0.0)
Present - 2 0 (0.0)
Present + 0 NA NA
>5 mm Absent - 15 2 (13.3)
Absent + 10 2 (20.0)
Present - 2 0 (0.0)
Present + 7 5 (71.4)
Yes (*2) ≤5 mm Absent - 2 0 (0.0)
Absent + 0 NA NA
Present - 1 0 (0.0)
Present + 2 2 (100.0)
>5 mm Absent - 19 7 (36.8)
Absent + 12 8 (66.7)
Present - 7 7 (100.0)
Present + 12 11 (91.7)
All cases (*3) ≤5 mm Absent - 11 0 (0.0)
Absent + 4 0 (0.0)
Present - 3 0 (0.0)
Present + 2 2 (100.0)
>5 mm Absent - 34 9 (26.5)
Absent + 24 10 (41.7)
Present - 9 7 (77.8)
Present + 19 16 (84.2)
NA: Data not available since any case was observed in this situation.
(*1) Eight cases were not included in this group because they did have either tumor depth or perineural information. SOD2 expression was positive in three of
them. All those cases had no lymph node metastasis.
(*2) Four cases were not included in this group because they did have either tumor depth or perineural information. SOD2 expression was positive in one of
them. All those cases had no lymph node metastasis.
(*3) Two cases with unknown clinical status of inguinal nodes were included in this group. Both cases had tumor depth > 5 mm, no perineural invasion, positive
SOD2 expression and no lymph node metastasis.
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malignant potential of several transformed cell lines
[10,16]. Conversely, it can be anticipated that SOD2 up-
regulation may reduce the level of ROS in tumor cells.
This may prevent the accumulation of life incompatible
levels of DNA and other macromolecules damage, pro-
tecting neoplastic cells from intrinsic cell death mecha-
nisms and favoring their survival and spread [8,9].
Analysis of SOD2 expression conducted in solid
tumor samples including colorectal [17,18], gastric and
esophageal [19,20], oral [21], lung [22-24], brain [25],
cervical [11] and skin [26] carcinomas have often asso-
ciated its up-regulation with metastasis and poor dis-
ease outcome. The molecular mechanisms underlying
increased SOD2 and metastasis include the alteration of
several cellular pathways. It has been observed that
SOD2 overexpression increases matrix metalloprotein-
ases (MMPs)-1, −2, −3, −7, −10, −9 and −11 mRNA
levels. In the case of MMP-1 this has been attributed to
the activation of the Ras/MAP/extracellular signal-
regulated kinase signaling cascade. In the same study
SOD2 upregulation was associated with enhanced meta-
static potential of fibrosarcoma cells in an animal model
[27]. Since MMPs play a critical role in the metastatic
process it can be argued that the association between in-
creased SOD2 and poor prognosis observed in certain
tumors may be attributed to elevated MMP production/
activity. A recent study showed that SOD2 expression
was sufficient to overcome ROS mediated growth arrest
in prostate carcinoma cells [28]. Besides it was observed
that elevated SOD2 levels confer resistance to ROS me-
diated anoikis in mammary epithelial cells in a process
dependent on NFκB activation [29]. Since anoikis resis-
tance is essential for tumor metastasis the anti-anoikis
activity of SOD2 implicates this enzyme in the
metastatic process. We can, therefore, speculate that
increased SOD2 levels may confer an adaptive advan-
tage to tumor cells favoring disease establishment and
progression.
We have previously reported that SOD2 is differen-
tially expressed between normal and HPV immortalized
keratinocytes [30]. Furthermore, we have recently shown
that SOD2 protein expression level is a potential bio-
marker for the characterization of different stages of
cervical neoplasia, which is etiologically linked with
infection with high-risk HPV types [11]. A proportion of
penile cancers are also associated with HPV, mostly
HPV16. In fact, recent evidence suggests that these
viruses, particularly HPV16, may be associated with up
to 48% of all penile tumors [31].
In the present study no association between SOD2 ex-
pression and HPV infection was observed. HPV DNA
was detected in 20.8% of the samples analyzed which
is below the HPV positivity data reported by others
[31,32]. This result is not due to quality of the DNA
recovered from the paraffinized specimens since >98% of
them tested positive for globin. The low proportion of
HPV-positive specimens detected probably reflects the
fact that in our study most of the samples analyzed are
of SCC of the usual histological type, which is less
frequently associated with HPV infection. Using explora-
tory logistic regression we observed that SOD2 expres-
sion in more than 50% of the cells was an independent
predictive factor of lymph node metastasis as were other
well documented clinical-pathologic variables such as
palpable suspicious nodes, tumor depth >5 mm and
perineural invasion [33-36].
Although SOD2 expression was clearly an independent
predictive factor of inguinal lymph node metastasis in
the multivariate model, its real contribution in clinical
practice remains to be determined. Table 5 demonstrates
that tumor depth information is able to determine itself
the presence of node metastasis, regardless the status of
inguinal node in the clinical exam and perineural inva-
sion status. Our results show that SOD2 expression has
some value by increasing the risk of metastasis when the
tumor depth was greater than 5 mm. All cases of in-
guinal metastasis, but two, occurred when the tumor
depth was greater than 5 mm. Interestingly, the two
cases in which lymph node metastasis was observed
when tumor depth was less than 5 mm had positive
SOD2 immunoexpression. Coincidently, those cases had
palpable suspicious lymph nodes in inguinal clinical
exam. The implication of SOD2 expression in thin penile
tumors is uncertain and should be interpreted with cau-
tion because a limited number of cases in this particular
setting were observed. However, the potential clinical
implications of this observation as well as the contribu-
tion of SOD2 assessment in clinical practice warrants
further studies.
Conclusions
SOD2 expression predicts regional lymph node metasta-
sis in usual type squamous cell carcinomas of the penis.
Further studies are needed to determine the clinical im-
plication of this factor.
Additional files
Additional file 1: Immunohistochemical analysis of SOD2
Expression in penile samples. Representative immunoreactivity of
SOD2 in normal penile epithelium (A) and usual penile squamous cell
carcinomas (B-D). Less than 50% of stained cells were observed in (B)
while (C) and (D) showed more than 50% of stained cells. Magnification:
200x.
Additional file 2: Frequency of HPV types in penile SCC samples.
Frequency of HPV types in penile SCC samples.
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